The new oral insulin utilizes nano-scale material for 1/10,000th the width of a human hair, to protect insulin molecules from stomach acid and act as a "nano-carrier." Developed by the University of Sydney Nano Institute, it enhances insulin absorption in human intestinal tissue. Human trials are slated for 2025. Additionally, it reacts to blood sugar levels, releasing insulin as needed, potentially reducing injection-related adverse effects.
The new oral insulin utilizes nano-scale material for 1/10,000th the width of a human hair, to protect insulin molecules from stomach acid and act as a "nano-carrier." Developed by the University of Sydney Nano Institute, it enhances insulin absorption in human intestinal tissue. Human trials are slated for 2025. Additionally, it reacts to blood sugar levels, releasing insulin as needed, potentially reducing injection-related adverse effects.